ERA® 子宮內膜容受性檢測

由Igenomix 開發並取得唯一專利權的子宮內膜容受性檢測（ERA）是專為子宮內膜容受性所設計的檢測。

這項技術是利用NGS分析248個與子宮內膜容受性狀態有關的基因表現。

已有多項研究證實ERA 檢測在偵測與容受性有關的基因表現圖譜，具有高靈敏度和特異性。利用ERA檢測，可在患者進行人工生殖技前，檢測其個人著床窗期。

進行ERA時，Igenomix 特有的AI演算法會先分析取自子宮內膜組織樣本的RNA，依RNA表現圖譜，再將其分類為容受性或非容受性。

若子宮內膜結果是非容受性，ERA檢測能夠找出專屬每一位患者的個人著床窗期。

Women who have experienced implantation failure with morphologically good quality embryos.
Women with a morphologically normal uterus and normal endometrial thickness (≥ 6 mm), where the uterus and endometrium are unlikely to be the problem.

90 % of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:

There is a risk (<5%) to get a non-informative result, in which the biopsy procedure has failed to obtain a sufficient quantity and/or quality of tissue to be able to make a diagnosis. If this should occur a new biopsy will be required.

The aim of this test Is to provide physicians with an objective molecular diagnosis of the patient´s endometrial timing of receptivity. Depending on the results of this test, the physician may use it as a guide for personalized embryo transfer.

Pregnancy is not guaranteed, even with a receptive result. Poor embryo quality, genetic abnormalities, or previous pathologies can also reduce the likelihood of becoming pregnant.

The ERA® does not test for any other endometrial pathology and does not asses or provide a prediction for the health of a subsequent pregnancy.

ERA is backed by 33 publications; 29 from Igenomix and 4 external publications.
Proprietary algorithm based on machine learning that minimizes the need for second biopsy (90% of cases).
Allows clinicians to identify transition phases with 12 hours shifts.
Randomized clinical trial (NCT01954758) RCT proves cumulative live birth rate increases +16 points VS classic frozen blastocyst transfer in first appointment patients: